Celine Chaaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Celine Chaaya has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Nimesh A. Patel
Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA
15 shared publications - Sandra Hoyek
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
9 shared publications - Francisco Altamirano
Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
6 shared publications - Efren Gonzalez
Department of Ophthalmology Boston Children's Hospital Boston Massachusetts USA
5 shared publications - Muhammad Abidi
Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
5 shared publications - Ryan Sameen Meshkin
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA
5 shared publications
Latest Publications
- 29 October 2026
- Published by Elsevier in Ophthalmology Retina
Validation of the TWO-ROP Algorithm in the Shenzhen Prematurity Eye Study
- 29 October 2026
- Published by Elsevier in Ophthalmology Retina
Validation of the TWO-ROP Algorithm in the Shenzhen Prematurity Eye Study
- 23 October 2026
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
Novel Ab Externo Rescue Technique of a Dislocated Four-point Scleral-Fixated Intraocular Lens
Purpose: The rescue of a dislocated scleral-sutured intraocular lens (IOL) remains surgically challenging. We report a novel, flapless, cornea-based ab externo technique for rescuing a dislocated scleral-fixated Akreos AO60 IOL. Case: A 59-year-old male with a history of remote left eye (OS) trauma complicated by glaucoma and retinal detachment status post repair, presented with decreased vision OS following acute blunt ocular trauma. The ocular examination revealed hand motion (LogMAR -2.70) vision and posterior dislocation of a previously scleral-fixated Akreos AO60 IOL. A core and peripheral vitrectomy were performed, and the IOL was relocated to the anterior chamber. Using corneal paracentesis and a 2.4mm main wound, each of the four-lens haptics was externalized and threaded with 8-0 GORE-TEX sutures. The distal suture followed by the proximal suture was passed into the anterior chamber and retrieved through the prior sclerotomies. The IOL was then reposited in the posterior chamber and sutured at sclerotomy sites for fixation. The best-corrected visual acuity improved from hand motion back to baseline of 20/70 (LogMAR 0.54) at follow-up, with no complications observed. Results: A dislocated Akreos AO60 four-haptic IOL was successfully rescued and re-fixated with stable centration with a novel ab externo approach. This technique provides an effective method with limited manipulation and small wounds. Conclusion: The ab externo technique provides an approach for rescuing dislocated four-haptic lenses, such as the Akreos AO60.
- 23 October 2026
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
Novel Ab Externo Rescue Technique of a Dislocated Four-point Scleral-Fixated Intraocular Lens
Purpose: The rescue of a dislocated scleral-sutured intraocular lens (IOL) remains surgically challenging. We report a novel, flapless, cornea-based ab externo technique for rescuing a dislocated scleral-fixated Akreos AO60 IOL. Case: A 59-year-old male with a history of remote left eye (OS) trauma complicated by glaucoma and retinal detachment status post repair, presented with decreased vision OS following acute blunt ocular trauma. The ocular examination revealed hand motion (LogMAR -2.70) vision and posterior dislocation of a previously scleral-fixated Akreos AO60 IOL. A core and peripheral vitrectomy were performed, and the IOL was relocated to the anterior chamber. Using corneal paracentesis and a 2.4mm main wound, each of the four-lens haptics was externalized and threaded with 8-0 GORE-TEX sutures. The distal suture followed by the proximal suture was passed into the anterior chamber and retrieved through the prior sclerotomies. The IOL was then reposited in the posterior chamber and sutured at sclerotomy sites for fixation. The best-corrected visual acuity improved from hand motion back to baseline of 20/70 (LogMAR 0.54) at follow-up, with no complications observed. Results: A dislocated Akreos AO60 four-haptic IOL was successfully rescued and re-fixated with stable centration with a novel ab externo approach. This technique provides an effective method with limited manipulation and small wounds. Conclusion: The ab externo technique provides an approach for rescuing dislocated four-haptic lenses, such as the Akreos AO60.
- 28 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment
Background/Aims: Aggressive retinopathy of prematurity (A-ROP) is a severe subtype of ROP that can require repeated treatment yet risk factors for retreatment remain incompletely defined. This study aims to identify risk factors for anti-vascular endothelial growth factor (VEGF) re-injection in A-ROP across US-born and non-US-born infants. Methods: Data from premature infants with ROP were collected across 23 sites (16 USA, 7 non-USA) from 2007 to 2021. A-ROP re-injection risk was evaluated using generalised estimating equations, adjusted for birth weight (BW), gestational age (GA) at birth, ROP zone at injection, hospital site and initial anti-VEGF agent. Results: Of 1677 examined eyes, 1600 had ROP; 283 had A-ROP (mean BW 712 g, mean GA 24.8 weeks) and 1317 had non-A-ROP (mean BW 812 g, mean GA 25.9 weeks). Infants with A-ROP had lower mean BW and GA (p < 0.001). Across A-ROP cases, each 100 g increase in BW decreased re-injection risk by 26% (p=0.041). Compared with bevacizumab, ranibizumab was associated with a higher risk of re-injection in A-ROP eyes (risk ratio=4.82, p=0.009). ROP zone II was associated with a 2.48-fold higher risk of re-injection than zone I (p = 0.014), which was attenuated after correction for bilaterality. Conclusions and relevance: A-ROP is associated with lower BW, lower GA at birth and more posterior ROP zone than non-A-ROP. Lower BW and initial ranibizumab treatment are related to greater risk of repeat anti-VEGF injection. There was more retreatment in zone II A-ROP eyes compared with those in zone I, which did not persist after correction for bilaterality.
- 28 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aggressive retinopathy of prematurity: characteristics and risk factors for retreatment
Background/Aims: Aggressive retinopathy of prematurity (A-ROP) is a severe subtype of ROP that can require repeated treatment yet risk factors for retreatment remain incompletely defined. This study aims to identify risk factors for anti-vascular endothelial growth factor (VEGF) re-injection in A-ROP across US-born and non-US-born infants. Methods: Data from premature infants with ROP were collected across 23 sites (16 USA, 7 non-USA) from 2007 to 2021. A-ROP re-injection risk was evaluated using generalised estimating equations, adjusted for birth weight (BW), gestational age (GA) at birth, ROP zone at injection, hospital site and initial anti-VEGF agent. Results: Of 1677 examined eyes, 1600 had ROP; 283 had A-ROP (mean BW 712 g, mean GA 24.8 weeks) and 1317 had non-A-ROP (mean BW 812 g, mean GA 25.9 weeks). Infants with A-ROP had lower mean BW and GA (p < 0.001). Across A-ROP cases, each 100 g increase in BW decreased re-injection risk by 26% (p=0.041). Compared with bevacizumab, ranibizumab was associated with a higher risk of re-injection in A-ROP eyes (risk ratio=4.82, p=0.009). ROP zone II was associated with a 2.48-fold higher risk of re-injection than zone I (p = 0.014), which was attenuated after correction for bilaterality. Conclusions and relevance: A-ROP is associated with lower BW, lower GA at birth and more posterior ROP zone than non-A-ROP. Lower BW and initial ranibizumab treatment are related to greater risk of repeat anti-VEGF injection. There was more retreatment in zone II A-ROP eyes compared with those in zone I, which did not persist after correction for bilaterality.
- 21 July 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Cost Analysis of Aflibercept 8 mg Versus Aflibercept 2 mg for the Treatment of Diabetic Macular Edema in the PHOTON Trial
Purpose: To compare the direct and indirect costs of aflibercept 8 mg with aflibercept 2 mg in patients with diabetic macular edema (DME) using the published data from the PHOTON trial. Methods: Three groups of patients with DME were compared: 163 patients under a protocol of aflibercept 2 mg every 8 weeks, 328 patients under a protocol of aflibercept 8 mg every 12 weeks, and 167 patients under a protocol of aflibercept 8 mg every 16 weeks. A model-based comparative analysis was conducted using estimates of direct and indirect costs based on the mean number of injection visits and mean number of injections administered at the end of 96 weeks in the PHOTON aflibercept 8 mg clinical trial. The costs were adjusted for inflation to 2025 US dollars. Results: Using point estimates of real-world data, patients in the aflibercept 8 mg every 16 weeks group had the lowest overall total costs (mean $32,259.54), followed by those in the aflibercept 8 mg every 12 weeks group (mean $37,550.14). Patients in the aflibercept 2 mg every 8 weeks group had the highest total costs (mean $41,124.26). Cost differences were primarily driven by the higher number of injection visits in the 2 mg every 8 weeks regimen compared with the higher-dose, extended-interval 8 mg schedules at 96 weeks. Multi-way deterministic sensitivity analysis showed that the aflibercept 8 mg every 16 weeks regimen was the least costly option across all 10 000 Monte Carlo cost simulations. Conclusions: Across both deterministic and simulated analyses, aflibercept 8 mg at extended dosing intervals (every 12 or 16 weeks) resulted in statistically significant cost savings compared with the standard 2 mg every 8 weeks regimen.
- 21 July 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Cost Analysis of Aflibercept 8 mg Versus Aflibercept 2 mg for the Treatment of Diabetic Macular Edema in the PHOTON Trial
Purpose: To compare the direct and indirect costs of aflibercept 8 mg with aflibercept 2 mg in patients with diabetic macular edema (DME) using the published data from the PHOTON trial. Methods: Three groups of patients with DME were compared: 163 patients under a protocol of aflibercept 2 mg every 8 weeks, 328 patients under a protocol of aflibercept 8 mg every 12 weeks, and 167 patients under a protocol of aflibercept 8 mg every 16 weeks. A model-based comparative analysis was conducted using estimates of direct and indirect costs based on the mean number of injection visits and mean number of injections administered at the end of 96 weeks in the PHOTON aflibercept 8 mg clinical trial. The costs were adjusted for inflation to 2025 US dollars. Results: Using point estimates of real-world data, patients in the aflibercept 8 mg every 16 weeks group had the lowest overall total costs (mean $32,259.54), followed by those in the aflibercept 8 mg every 12 weeks group (mean $37,550.14). Patients in the aflibercept 2 mg every 8 weeks group had the highest total costs (mean $41,124.26). Cost differences were primarily driven by the higher number of injection visits in the 2 mg every 8 weeks regimen compared with the higher-dose, extended-interval 8 mg schedules at 96 weeks. Multi-way deterministic sensitivity analysis showed that the aflibercept 8 mg every 16 weeks regimen was the least costly option across all 10 000 Monte Carlo cost simulations. Conclusions: Across both deterministic and simulated analyses, aflibercept 8 mg at extended dosing intervals (every 12 or 16 weeks) resulted in statistically significant cost savings compared with the standard 2 mg every 8 weeks regimen.
- 30 June 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Structure–Function Correlation With Optical Coherence Tomography–Derived Macular Thickness and Macular Microperimetry in Children, Adolescents, and Young Adults With Sickle Cell Disease
Purpose: To evaluate the relationship between macular retinal thickness on optical coherence tomography (OCT) and retinal sensitivity on microperimetry in children, adolescents, and young adults with sickle cell disease. Methods: This cross-sectional study included 63 eyes of 34 patients with sickle cell disease. Data included demographics, macular retinal thickness determined by OCT, and retinal sensitivity on Macular Integrity Assessment (CenterVue) using a 68-point, 10-degree grid under mesopic conditions. Total retinal thickness was measured in the central, parafoveal, and perifoveal regions. The relationship between OCT macular thickness and retinal sensitivity on mesopic microperimetry was assessed in specific macular regions, including differences by peripheral sickle cell retinopathy status. Results: The median age of the 34 patients (63 eyes) was 14.6 years, and the median best-corrected visual acuity (BCVA) at the time of testing was 0 logMAR (Snellen 20/20). Of the 63 eyes, 55 (87.3%) had ≤30% fixation loss and thus were considered for the primary analysis. In multivariate regression analyses adjusted for patient age, BCVA, sickle cell genotype, sex, and race and ethnicity, decreased retinal sensitivity measured by microperimetry was associated with a decrease in OCT macular thickness (β = 0.06, 95% CI, 0.015–0.104; P = .009). Moreover, eyes with peripheral sickle cell retinopathy had lower temporal perifoveal retinal sensitivity on mesopic microperimetry compared with eyes without retinopathy (β = −6.3, 95% CI, −10.9 to −1.7; P = .008). BCVA at the time of testing was not associated with decreased macular sensitivity ( P = .817) or with decreased OCT macular thickness ( P = .086). Conclusions: Children, adolescents, and young adult patients with sickle cell maculopathy demonstrated reduced visual function, which was correlated with the degree of retinal thinning. Eyes with peripheral sickle cell retinopathy had lower temporal macular sensitivity compared with eyes without peripheral retinopathy. There was no difference in visual acuity between the groups, suggesting that functional tests are required to assess vision in sickle cell disease comprehensively.
- 30 June 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Structure–Function Correlation With Optical Coherence Tomography–Derived Macular Thickness and Macular Microperimetry in Children, Adolescents, and Young Adults With Sickle Cell Disease
Purpose: To evaluate the relationship between macular retinal thickness on optical coherence tomography (OCT) and retinal sensitivity on microperimetry in children, adolescents, and young adults with sickle cell disease. Methods: This cross-sectional study included 63 eyes of 34 patients with sickle cell disease. Data included demographics, macular retinal thickness determined by OCT, and retinal sensitivity on Macular Integrity Assessment (CenterVue) using a 68-point, 10-degree grid under mesopic conditions. Total retinal thickness was measured in the central, parafoveal, and perifoveal regions. The relationship between OCT macular thickness and retinal sensitivity on mesopic microperimetry was assessed in specific macular regions, including differences by peripheral sickle cell retinopathy status. Results: The median age of the 34 patients (63 eyes) was 14.6 years, and the median best-corrected visual acuity (BCVA) at the time of testing was 0 logMAR (Snellen 20/20). Of the 63 eyes, 55 (87.3%) had ≤30% fixation loss and thus were considered for the primary analysis. In multivariate regression analyses adjusted for patient age, BCVA, sickle cell genotype, sex, and race and ethnicity, decreased retinal sensitivity measured by microperimetry was associated with a decrease in OCT macular thickness (β = 0.06, 95% CI, 0.015–0.104; P = .009). Moreover, eyes with peripheral sickle cell retinopathy had lower temporal perifoveal retinal sensitivity on mesopic microperimetry compared with eyes without retinopathy (β = −6.3, 95% CI, −10.9 to −1.7; P = .008). BCVA at the time of testing was not associated with decreased macular sensitivity ( P = .817) or with decreased OCT macular thickness ( P = .086). Conclusions: Children, adolescents, and young adult patients with sickle cell maculopathy demonstrated reduced visual function, which was correlated with the degree of retinal thinning. Eyes with peripheral sickle cell retinopathy had lower temporal macular sensitivity compared with eyes without peripheral retinopathy. There was no difference in visual acuity between the groups, suggesting that functional tests are required to assess vision in sickle cell disease comprehensively.
- 25 June 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Acute Macular Neuroretinopathy and Peripheral Retinal Abnormalities in a Patient With Adams–Oliver Syndrome
Purpose: To report a case of acute macular neuroretinopathy in a 22-year-old woman with a history of Adams–Oliver syndrome and associated peripheral retinal vascular anomalies. Methods: A single case was reviewed. Results: A 22-year-old woman with a history of Adams–Oliver syndrome presented with a central scotoma and was found to have a paracentral outer retinal lesion consistent with acute macular neuroretinopathy. Retinal examination and multimodal imaging revealed peripheral retinal vascular anomalies, including bilateral peripheral telangiectasias, avascular retina, venous shunting, supernumerary branching, and vascular tortuosity, consistent with familial exudative vitreoretinopathy despite negative genetic testing. Conclusions: This case expands the ocular spectrum of Adams–Oliver syndrome and highlights the importance of routine ophthalmic surveillance in affected patients.
- 25 June 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Acute Macular Neuroretinopathy and Peripheral Retinal Abnormalities in a Patient With Adams–Oliver Syndrome
Purpose: To report a case of acute macular neuroretinopathy in a 22-year-old woman with a history of Adams–Oliver syndrome and associated peripheral retinal vascular anomalies. Methods: A single case was reviewed. Results: A 22-year-old woman with a history of Adams–Oliver syndrome presented with a central scotoma and was found to have a paracentral outer retinal lesion consistent with acute macular neuroretinopathy. Retinal examination and multimodal imaging revealed peripheral retinal vascular anomalies, including bilateral peripheral telangiectasias, avascular retina, venous shunting, supernumerary branching, and vascular tortuosity, consistent with familial exudative vitreoretinopathy despite negative genetic testing. Conclusions: This case expands the ocular spectrum of Adams–Oliver syndrome and highlights the importance of routine ophthalmic surveillance in affected patients.
- 23 June 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 290, 246-251
Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation
- 23 June 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 290, 246-251
Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation